title: Bone formation and remodeling of three different dental implant surfaces with Escherichia coli-derived recombinant human bone morphogenetic protein 2 in a rabbit model.
abstract: OBJECTIVE
  The objective of this study was to analyze orthotropic bone formation and remodeling of three different dental implant surfaces with and without recombinant human bone morphogenetic protein 2 derived from Escherichia coli (ErhBMP-2) in a rabbit model.
  
  
  METHODS
  Resorbable blasting media (RBM); sandblasted, large-grit, acid-etched (SLA); and magnesium-incorporated oxidized (MgO) implant surfaces were coated with ErhBMP-2 (1.5 mg/mL). The implants were placed into the proximal tibia in six New Zealand White rabbits. Each rabbit received six different implants (three coated with ErhBMP-2 in one tibia and three uncoated implants in the other tibia), and the sites were closed, submerging the implants. The animals received alizarin (at 2 weeks), calcein (at 4 weeks), and tetracycline (at 6 weeks) fluorescent bone markers, and were euthanized at 8 weeks for histomorphometric analysis.
  
  
  RESULTS
  The amount of ErhBMP-2 coating was 9.6 ± 0.4 μg per MgO implant, 14.5 ± 0.6 μg per RBM implant, and 29.9 ± 3.8 μg per SLA implant. Clinical healing was uneventful. Mean bone-to-implant contact (± standard deviation) for the ErhBMP-2/RBM (35.4% ± 5.1%) and ErhBMP-2/MgO (33.4 % ± 13.2%) implants was significantly greater compared with RBM (23.6% ± 6.2%) and MgO (24.9% ± 2.7%) implants (P < .05). Considering the mean bone-to-implant contact in cortical bone, ErhBMP-2/SLA implants (32.9% ± 7.8%) showed lower bone-to-implant contact in cortical bone than all other implant variations (range, 39.9% ± 18.1% to 51.3% ± 9.2%; P < .05). There were no remarkable differences in new bone area, with minor differences between implants.
  
  
  CONCLUSIONS
  Within the limits of study, it was found that the absorbed ErhBMP-2 dose varied with implant surface characteristics, influencing local bone formation and remodeling.
authors.affiliation: Periodontology and Research Institute for Periodontal Regeneration, Yonsei University College of Dentistry, Seoul, Korea. kscho@yuhs.ac
authors.forename: Jae-Kwan
authors.initials: JK
authors.lastname: Lee
authors.forename: Lee-Ra
authors.initials: LR
authors.lastname: Cho
authors.forename: Heung-Sik
authors.initials: HS
authors.lastname: Um
authors.forename: Beom-Seok
authors.initials: BS
authors.lastname: Chang
authors.forename: Kyoo-Sung
authors.initials: KS
authors.lastname: Cho
mesh_terms: D000818:Animals; D000880:Anthraquinones / Q000008:administration & dosage / Q000493:pharmacokinetics; D055396:Bone Morphogenetic Protein 2 / Q000008:administration & dosage* / Q000493:pharmacokinetics; D016723:Bone Remodeling / Q000502:physiology*; D015921:Dental Implants; D016503:Drug Delivery Systems / Q000379:methods; D004926:Escherichia coli / Q000378:metabolism; D005452:Fluoresceins / Q000008:administration & dosage / Q000493:pharmacokinetics; D006801:Humans; D016348:Osseointegration / Q000502:physiology*; D010012:Osteogenesis / Q000502:physiology*; D011817:Rabbits; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000493:pharmacokinetics; D013499:Surface Properties; D013752:Tetracycline / Q000008:administration & dosage / Q000493:pharmacokinetics; D013977:Tibia; D014025:Titanium; D016212:Transforming Growth Factor beta / Q000008:administration & dosage* / Q000493:pharmacokinetics
chemical_list: D000880:Anthraquinones; D055396:Bone Morphogenetic Protein 2; D015921:Dental Implants; D005452:Fluoresceins; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; C499469:recombinant human bone morphogenetic protein-2; C010078:alizarin; D014025:Titanium; D013752:Tetracycline; C007740:fluorexon